A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
基本信息
- 批准号:10722602
- 负责人:
- 金额:$ 70.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2029-03-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
Acquired severe aplastic anemia (SAA) is a rare bone marrow failure disorder with an annual incidence of 3
per million in North America (>300 cases < age 25 in the US yearly). The disease can be treated and often
cured by either immune suppression therapy (IST) or hematopoietic stem cell transplantation (HSCT), with the
recommended approach in SAA being early matched sibling donor bone marrow transplantation (BMT).
However, only 20% of patients have sibling donors, consequently, the large majority of patients receive IST for
initial therapy. From initiation of IST it takes 2-6 months to see hematologic improvement, with responses
occurring 70-80% of the time in children. Unfortunately, 20-30% of patients eventually relapse, requiring
additional immune suppression, and some become cyclosporin-dependent. The results of matched unrelated
donor (URD) BMT for SAA has improved significantly over the past decade, with studies reporting similar
outcomes for BMT using URD compared to MSD. Although these data are provocative, URD BMT carries
significant risks, and most consensus opinions still conclude that IST should be considered standard of care
when a matched sibling donor is not available, until a definitive study shows otherwise. To address this
challenge, the North American Pediatric Aplastic Anemia Consortium (NAPAAC), in collaboration with the
Pediatric Transplantation and Cellular Therapy Consortium (PTCTC), conducted an NHLBI R34-funded pilot
trial to determine feasibility and safety of randomizing between IST and URD BMT. Our recently published
results of the first 23 patients showed high rates of acceptance of randomization, receipt of randomized
therapy without significant adverse events, and rapid institution of definitive therapy (IST or BMT) (Pulsipher
et al., Pediatric Blood and Cancer, 2020). Having demonstrated feasibility, we submit this application to
support a paradigm-changing randomized trial in partnership with the Center for International Blood and
Marrow Transplant Research (CIBMTR). The study proposes a multi-center phase III trial to compare the
percentage of newly diagnosed SAA patients with immune suppression-free survival with adequate counts
(ISFS-AC) at 2-years between those randomized to IST vs 9-10/10 HLA matched URD BMT. The study will
also address patient-reported outcomes and fertility preservation in each arm and explore critical biological
correlates including assessing germline genetic mutations associated with pediatric SAA that may affect
response to BMT or IST and the development of clonal hematopoiesis following IST vs BMT in pediatric SAA.
The study proposed would represent the largest randomized study in pediatric SAA ever attempted with the
goal of providing practice-altering conclusions to the field.
项目总结/摘要
获得性重型再生障碍性贫血(SAA)是一种罕见的骨髓衰竭性疾病,
在北美每百万人(在美国每年>300例<25岁)。这种疾病是可以治疗的,
通过免疫抑制疗法(IST)或造血干细胞移植(HSCT)治愈,
SAA中推荐的方法是早期匹配的同胞供体骨髓移植(BMT)。
然而,只有20%的患者有兄弟姐妹供体,因此,绝大多数患者接受IST的时间为
初始治疗从IST开始,需要2-6个月才能看到血液学改善,
70-80%发生在儿童身上。不幸的是,20-30%的患者最终复发,需要
额外的免疫抑制,有些变得依赖环孢霉素。结果匹配无关
在过去的十年中,SAA的供体(URD)BMT有了显著改善,研究报告类似
与MSD相比,使用URD的BMT结果。虽然这些数据是挑衅性的,URD BMT进行
重大风险,大多数共识意见仍然认为IST应被视为标准治疗
当没有匹配的同胞捐赠者时,直到确定的研究表明不是这样。为了解决这个
挑战,北美儿科再生障碍性贫血联盟(NAPAAC),与
儿科移植和细胞治疗联盟(PTCTC),进行了一项由NHLBI R34资助的试点
确定IST和URD BMT之间随机化的可行性和安全性的试验。我们最近出版的
前23名患者的结果显示,接受随机化的比例很高,
无显著不良事件的治疗,以及快速确定性治疗(IST或BMT)(Pulsipher
例如,儿科血液和癌症,2020)。经论证可行性后,我们将此申请提交给
与国际血液中心合作,支持一项改变范式的随机试验,
骨髓移植研究(CIBMTR)。该研究提出了一项多中心III期试验,
新诊断SAA患者的无免疫抑制生存率(计数充足)百分比
随机分配至IST组与9-10/10 HLA匹配的URD BMT组患者之间的2年(ISFS-AC)。这项研究将
还讨论了每组患者报告的结局和生育力保存,并探讨了关键的生物学
相关性,包括评估与儿童SAA相关的生殖系基因突变,
儿童SAA患者对BMT或IST的反应以及IST与BMT后克隆性造血的发展。
这项研究将代表有史以来最大的儿童SAA随机研究,
目标是为该领域提供改变实践的结论。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael A Pulsipher其他文献
Michael A Pulsipher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael A Pulsipher', 18)}}的其他基金
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10368246 - 财政年份:2022
- 资助金额:
$ 70.48万 - 项目类别:
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors
确定儿童造血干细胞捐献者健康相关生活质量不佳的预测因素
- 批准号:
10319994 - 财政年份:2018
- 资助金额:
$ 70.48万 - 项目类别:
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors
确定儿童造血干细胞捐献者健康相关生活质量不佳的预测因素
- 批准号:
10079501 - 财政年份:2018
- 资助金额:
$ 70.48万 - 项目类别:
RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life
RDSafe:HSC 捐献者安全和生活质量的多机构研究
- 批准号:
8514682 - 财政年份:2009
- 资助金额:
$ 70.48万 - 项目类别:
RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life
RDSafe:HSC 捐献者安全和生活质量的多机构研究
- 批准号:
8197785 - 财政年份:2009
- 资助金额:
$ 70.48万 - 项目类别:
RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life
RDSafe:HSC 捐献者安全和生活质量的多机构研究
- 批准号:
7581672 - 财政年份:2009
- 资助金额:
$ 70.48万 - 项目类别:
RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life
RDSafe:HSC 捐献者安全和生活质量的多机构研究
- 批准号:
7756660 - 财政年份:2009
- 资助金额:
$ 70.48万 - 项目类别:
Blood and Marrow Transplant Clinical Trials Network
血液和骨髓移植临床试验网络
- 批准号:
8174197 - 财政年份:2001
- 资助金额:
$ 70.48万 - 项目类别:
Blood and Marrow Transplant Clinical Trials Network
血液和骨髓移植临床试验网络
- 批准号:
8316291 - 财政年份:2001
- 资助金额:
$ 70.48万 - 项目类别:
Blood and Marrow Transplant Clinical Trials Network
血液和骨髓移植临床试验网络
- 批准号:
7664303 - 财政年份:2001
- 资助金额:
$ 70.48万 - 项目类别:
相似国自然基金
全钒液流电池负极V(II)/V(III)电化学氧化还原的催化机理研究
- 批准号:2025JJ50094
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
吡咯烷生物碱所致肝窦阻塞综合征III区肝损伤的新机制——局部氨代谢紊乱
- 批准号:JCZRYB202500652
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
硅基III-V族亚微米线激光器的光场模式调控与耦合机理研究
- 批准号:JCZRQN202501004
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
MXene/nZVI@FH材料微域层界面调控水中砷(III)氧化迁移机制
- 批准号:2025JJ50319
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
HOXC8/OPN/CD44/EGFR轴介导的奥沙利铂耐药性在III期右半结肠癌耐药进展中的研究
- 批准号:2025JJ50694
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AI结合超声原始射频信号评估Bethesda III/IV类甲状腺肿瘤包膜和血管侵犯研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
硫化砷靶向VPS4B-ESCRT-III调控自噬溶酶体通路逆转三阴性乳腺癌顺铂耐药性的研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
ASPGR与MRC2双受体介导铱(III)配合物
脂质体抗肝肿瘤研究
- 批准号:
- 批准年份:2025
- 资助金额:10.0 万元
- 项目类别:省市级项目
Ap-Exo III 联合模式识别构建降尿酸药
物筛选新方法的研究
- 批准号:
- 批准年份:2025
- 资助金额:10.0 万元
- 项目类别:省市级项目
稻田土壤二氧化锰还原生成Mn(III)过程对As(III)的氧化-固定机制
- 批准号:2025JJ60246
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes
oPTion-DDR:一项随机 III 期试验,研究铂类和紫杉烷化疗对 DNA 损伤反应 (DDR) 基因改变的转移性去势抵抗性前列腺癌患者的影响
- 批准号:
477946 - 财政年份:2023
- 资助金额:
$ 70.48万 - 项目类别:
Operating Grants
Lomustine with or without reirradiation for first progression of glioblastoma: a pragmatic randomized phase III study
洛莫司汀联合或不联合再照射治疗胶质母细胞瘤首次进展:一项实用的随机 III 期研究
- 批准号:
10090678 - 财政年份:2023
- 资助金额:
$ 70.48万 - 项目类别:
EU-Funded
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
在不适合移植的新诊断多发性骨髓瘤老年人中进行固定持续时间 Daratumumab 与连续 Daratumumab 的 III 期非劣效随机对照试验 (RCT)
- 批准号:
478153 - 财政年份:2023
- 资助金额:
$ 70.48万 - 项目类别:
Operating Grants
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10368246 - 财政年份:2022
- 资助金额:
$ 70.48万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10600143 - 财政年份:2022
- 资助金额:
$ 70.48万 - 项目类别:
A Phase II/III randomized, placebo controlled, double blind study to evaluate the effects of up to 24 weeks of low dose pazopanib on HHT related epistaxis and anemia. IND#144808 June 25, 2020
一项 II/III 期随机、安慰剂对照、双盲研究,旨在评估长达 24 周的低剂量帕唑帕尼对 HHT 相关鼻出血和贫血的影响。
- 批准号:
10281794 - 财政年份:2022
- 资助金额:
$ 70.48万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10370775 - 财政年份:2022
- 资助金额:
$ 70.48万 - 项目类别:
Veterans Affairs seamless phase II/III randomized trial of STAndard systemic theRapy with or without PET-directed local therapy for OligoRecurrenT prostate cancer (VA STARPORT)
退伍军人事务部无缝 II/III 期 STAndard 全身治疗随机试验,有或没有 PET 定向局部治疗,用于治疗寡复发性前列腺癌 (VA STARPORT)
- 批准号:
10578677 - 财政年份:2021
- 资助金额:
$ 70.48万 - 项目类别:
A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children
阿奇霉素治疗 RSV 引起的儿童呼吸衰竭的 III 期随机对照试验
- 批准号:
10670177 - 财政年份:2021
- 资助金额:
$ 70.48万 - 项目类别:
A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children
阿奇霉素治疗 RSV 引起的儿童呼吸衰竭的 III 期随机对照试验
- 批准号:
10458679 - 财政年份:2021
- 资助金额:
$ 70.48万 - 项目类别: